Bronchitis - Pipeline Review, H2 2018

Bronchitis - Pipeline Review, H2 2018

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Bronchitis - Pipeline Review, H2 2018, provides an overview of the Bronchitis (Respiratory) pipeline landscape.

Bronchitis is an inflammation of the lining of bronchial tubes, which carry air to and from lungs. Symptoms include cough that produces mucus (sputum), which may be blood streaked, shortness of breath aggravated by exertion or mild activity, frequent respiratory infections that worsen symptom, wheezing, fatigue, ankle that affects both sides and headaches. Risk factors include smoking, low resistance and gastric reflux.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Bronchitis - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Bronchitis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bronchitis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Bronchitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 3, 3, 4 and 1 respectively.

Bronchitis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Bronchitis (Respiratory).
- The pipeline guide reviews pipeline therapeutics for Bronchitis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Bronchitis (Respiratory) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Bronchitis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Bronchitis (Respiratory)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Bronchitis (Respiratory).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Bronchitis (Respiratory) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Bronchitis - Overview
Bronchitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Bronchitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bronchitis - Companies Involved in Therapeutics Development
Advanced Inhalation Therapies (AIT) Ltd
AstraZeneca Plc
Daewon Pharm Co Ltd
DBV Technologies SA
F. Hoffmann-La Roche Ltd
Han Wha Pharma Co Ltd
Icure Pharmaceutical Inc
Kyorin Pharmaceutical Co Ltd
Merck & Co Inc
Onspira Therapeutics Inc
Orbis Biosciences Inc
Therabron Therapeutics Inc
Bronchitis - Drug Profiles
alteplase - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
alvelestat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CG-367 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cyclosporine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DW-1601 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
formoterol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HOB-051 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lascufloxacin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nitric oxide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pirfenidone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
prednisone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protein to Antagonize IL1B for Bronchiolitis Obliterans - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
respiratory syncytial virus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SNSP-146 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
solithromycin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YJP-40 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bronchitis - Dormant Projects
Bronchitis - Discontinued Products
Bronchitis - Product Development Milestones
Featured News & Press Releases
Apr 26, 2018: AIT Therapeutics Receives Patent Allowance for Delivery of Inhaled Nitric Oxide at Concentrations of at Least 160ppm for Treatment of Bronchiolitis in Infants
Dec 01, 2017: AIT Therapeutics Announces Publication of Its Phase 2 Trial in Bronchiolitis Patients in the Pediatric Pulmonology Journal
Nov 21, 2017: AIT Therapeutics to Hold Clinical Update Meeting on November 28, 2017
Jan 23, 2017: Therabron Therapeutics Receives Orphan Drug Designation in the European Union for CG367, Indicated for the Treatment of Bronchiolitis Obliterans Syndrome
Jun 23, 2015: Jubilant Life Sciences receives ANDA approval for Levofloxacin Tablets
Apr 21, 2015: Advanced Inhalation Therapies to Present AIT-RSV Clinical Data at Two Upcoming Medical Meetings
Feb 03, 2014: AIT To Present Noxcurebr At The Annual Meeting Of The Israeli Association Of Clinical Pediatrics
Jan 19, 2014: AIT To Present Phase II Clinical Data for NOxCureBR, A Treatment for Acute Bronchiolitis and RSV in Infants
Jan 15, 2013: DBV Technologies And INRA Receive Funding To Develop Pediatric Bronchiolitis Vaccine
Feb 11, 2010: PARI Pharma Enrolls First Patient In Phase IIb Study Of L-CsA
Jun 02, 2009: PARI Pharma Reports Successful Phase Ib Clinical Results For Inhaled Liposomal Cyclosporine A And Gains FDA Orphan Drug Designation For The Prevention And Treatment Of Bronchiolitis Obliterans
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables


Number of Products under Development for Bronchitis, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Bronchitis - Pipeline by Advanced Inhalation Therapies (AIT) Ltd, H2 2018
Bronchitis - Pipeline by AstraZeneca Plc, H2 2018
Bronchitis - Pipeline by Daewon Pharm Co Ltd, H2 2018
Bronchitis - Pipeline by DBV Technologies SA, H2 2018
Bronchitis - Pipeline by F. Hoffmann-La Roche Ltd, H2 2018
Bronchitis - Pipeline by Han Wha Pharma Co Ltd, H2 2018
Bronchitis - Pipeline by Icure Pharmaceutical Inc, H2 2018
Bronchitis - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2018
Bronchitis - Pipeline by Merck & Co Inc, H2 2018
Bronchitis - Pipeline by Onspira Therapeutics Inc, H2 2018
Bronchitis - Pipeline by Orbis Biosciences Inc, H2 2018
Bronchitis - Pipeline by Therabron Therapeutics Inc, H2 2018
Bronchitis - Dormant Projects, H2 2018
Bronchitis - Dormant Projects, H2 2018 (Contd..1), H2 2018
Bronchitis - Discontinued Products, H2 2018

List Of Figures


Number of Products under Development for Bronchitis, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

Tracheobronchitis Global Clinical Trials Review, H2, 2018

Tracheobronchitis Global Clinical Trials Review, H2, 2018The clinical trial report, Tracheobronchitis Global Clinical Trials Review, H2, 2018 provides an overview of Tracheobronchitis clinical trials scenario. This report provides top line

USD 2500 View Report

Bronchitis - Pipeline Review, H2 2018

Bronchitis - Pipeline Review, H2 2018Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Bronchitis - Pipeline Review, H2 2018, provides an overview of the Bronchitis (Respiratory) pipeline landscape.Bronchitis

USD 2000 View Report

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Pipeline Review, H2 2018

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Pipeline Review, H2 2018T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - CD28 is a proteins expressed on T

USD 3500 View Report

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Pipeline Review, H2 2018

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Pipeline Review, H2 2018Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4

USD 3500 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available